IBIO iBio, Inc.: Multiplikator Forward P/S

iBio, Inc. (IBIO) is currently in the pre-revenue research phase, meaning its market capitalization relies on future contracts. The application of AI to develop oncology antibodies ensures long-term patent protection and royalties. The business's forward P/S confirms market expectations, with the value stabilizing at 45.10. The company's success depends on test results and the willingness of pharma behemoths to license the developed vaccines.

This indicator compares the current market value of iBio, Inc. (IBIO) with projected sales volumes, allowing for an assessment of whether the asset is overvalued or undervalued relative to future cash flows. By analyzing the forward P/S based on forecasts, an investor can determine the extent to which the market has priced in future royalties from AI-driven molecule discovery and licensing revenues from antibodies within the immuno-oncology segment.